AI Summary
The article discusses the urgent need for diagnostic biomarkers and effective therapies for long COVID. It highlights the challenges of conducting clinical trials and suggests that grassroots clinical trials could provide a faster way to address this issue. The authors mention the limitations of large, well-funded academic centers in engaging with the problem.
Diagnostic biomarkers and effective therapies are urgently needed for the millions of people living with long COVID. But the challenges of designing and conducting clinical trials mean that only large, well-funded academic centres can engage with the problem.
Competing Interests
J.V.W. has received a speaker fee from Pfizer, but none of the authors has a conflict of interest.